R&D Solutions revenue is IQVIA's recognized revenue from outsourced clinical research, clinical trials, real-world research, and related R&D services.
IQVIA reported $2.575B of R&D Solutions revenue in Q2 2026, up 8.8% from $2.366B a year earlier. Constant-currency growth was 8.6%.
Revenue is the conversion point
Net new bookings and contracted backlog describe future work. Revenue records the portion recognized in the current period.
IQVIA also said R&D revenue excluding reimbursed expenses grew 6.7% on a reported basis, showing why pass-through investigator and travel costs can make headline revenue growth differ from underlying service growth.
Primary sources: IQVIA Q2 2026 Form 10-Q and Q2 2026 earnings release filed with the SEC.
Continue Research
Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.
Compare stocks
Compare recognized outsourced R&D revenue separately from bookings, backlog, and pass-through expense effects.
Explore more topics in the Financial Research Encyclopedia.